WALTHAM, Mass.--(BUSINESS WIRE)--Nomir Medical Technologies announced today the presentation of positive in vivo human data for its Noveon® direct optical energy device for treating methicillin-resistant Staphylococcus aureus (MRSA) colonization in the human nares (nose). The study demonstrated that this light-based treatment with the Noveon resulted in reversal of microbial resistance to generic topical 2% erythromycin paste. The study confirmed two years of in vitro experimentation that indicate the device’s method-of-action is due to a unique photo-inactivation effect. This patented method resulted in the eradication of erythromycin-resistant MRSA and erythromycin-resistant, methicillin-sensitive Staphylococcus aureus (MSSA) in the human nose, at safe energy densities and temperatures that are harmless to the delicate tissues of the nares. Nomir is presenting the data on Monday, December 8, 2008 at the TERMIS NA Annual Conference and Exhibition in San Diego, during Poster Session I, from 5:00 - 6:30 pm PST.
